CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference – PRNewswire

Posted: Published on December 7th, 2019

This post was added by Alex Diaz-Granados

MONMOUTH JUNCTION, N.J., Dec. 2, 2019 /PRNewswire/ --CytoSorbents Corporation(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorbblood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Piper Jaffray 31st Annual Healthcare Conference onThursday, December 5, 2019inNew York, NY, and meet with investors in 1x1 meetings throughout the day.

Piper Jaffray 31st Annual Healthcare Conference Where:Lotte New York Palace, 455 Madison Ave, New York, NY When:Thursday, December 5, 2019 from11:50AM-12:10PM ESTWebcast: Piper Jaffray 31st Annual Healthcare Conference Webcast Link

A live webcast of the presentation will be available at the above webcast link. An archived replay of the webcast will be available for 90 days following the event.

About CytoSorbents Corporation (NASDAQ:CTSO)

CytoSorbents Corporationis a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury.The Company has also initiated the company-sponsored U.K. TISORB trial evaluating the removal of ticagrelor in emergency cardiac surgery patients.CytoSorb has been used in more than 73,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately$29 millionfrom DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL, HemoDefend, VetResQ, K+ontrol, ContrastSorb, DrugSorb, and others.For more information, please visit the Company's websites at http://www.cytosorbents.com and http://www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC onMarch 7, 2019, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebookand Twitter

Cytosorbents Contact: Amy Vogel Investor Relations 732-398-5394 avogel@cytosorbents.com

Investor Relations Contact: Jeremy Feffer LifeSci Advisors 917-749-1494 jeremy@lifesciadvisors.com

Public Relations Contact: Joshua Berkman Rubenstein Public Relations 212-805-3055 jberkman@rubensteinpr.com

SOURCE CytoSorbents Corporation

http://www.cytosorbents.com

Continued here:

CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference - PRNewswire

Related Posts
This entry was posted in Cardiac Surgery. Bookmark the permalink.

Comments are closed.